» Articles » PMID: 10092879

Activation of a CGMP-stimulated CAMP Phosphodiesterase by Protein Kinase C in a Liver Golgi-endosomal Fraction

Overview
Journal Eur J Biochem
Specialty Biochemistry
Date 1999 Mar 27
PMID 10092879
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of Ca2+/phospholipid-dependent protein kinase (protein kinase C, PKC) to stimulate cAMP phosphodiesterase (PDE) activity in a liver Golgi-endosomal (GE) fraction was examined in vivo and in a cell-free system. Injection into rats of 4 beta-phorbol 12-myristate 13-acetate, a known activator of PKC, caused a rapid and marked increase in PKC activity (+325% at 10 min) in the GE fraction, along with an increase in the abundance of the PKC alpha-isoform as seen on Western immunoblots. Concurrently, 4 beta-phorbol 12-myristate 13-acetate treatment caused a time-dependent increase in cAMP PDE activity in the GE fraction (96% at 30 min). Addition of the catalytic subunit of protein kinase A (PKA) to GE fractions from control and 4 beta-phorbol 12-myristate 13-acetate-treated rats led to a comparable increase (130-150%) in PDE activity, suggesting that PKA is probably not involved in the in-vivo effect of 4 beta-phorbol 12-myristate 13-acetate. In contrast, addition of purified PKC increased (twofold) PDE activity in GE fractions from control rats but affected only slightly the activity in GE fractions from 4 beta-phorbol 12-myristate 13-acetate-treated rats. About 50% of the Triton-X-100-solubilized cAMP PDE activity in the GE fraction was immunoprecipitated with an anti-PDE3 antibody. On DEAE-Sephacel chromatography, three peaks of PDE were sequentially eluted: one early peak, which was stimulated by cGMP and inhibited by erythro-9 (2-hydroxy-3-nonyl) adenine (EHNA); a selective inhibitor of type 2 PDEs; and two retarded peaks of activity, which were potently inhibited by cGMP and cilostamide, an inhibitor of type 3 PDEs. Further characterization of peak I by HPLC resolved a major peak which was activated (threefold) by 5 microM cGMP and inhibited (87%) by 25 microM EHNA, and a minor peak which was insensitive to EHNA and cilostamide. 4 beta-Phorbol 12-myristate 13-acetate treatment caused a selective increase (2.5-fold) in the activity associated with DEAE-Sephacel peak I, without changing the K(m) value. These results suggest that PKC selectively activates a PDE2, cGMP-stimulated isoform in the GE fraction.

Citing Articles

Cyclic GMP and PKG Signaling in Heart Failure.

Numata G, Takimoto E Front Pharmacol. 2022; 13:792798.

PMID: 35479330 PMC: 9036358. DOI: 10.3389/fphar.2022.792798.


PDE2 Inhibits PKA-Mediated Phosphorylation of TFAM to Promote Mitochondrial Ca-Induced Colorectal Cancer Growth.

Zhao Y, Wang Y, Zhao J, Zhang Z, Jin M, Zhou F Front Oncol. 2021; 11:663778.

PMID: 34235078 PMC: 8256694. DOI: 10.3389/fonc.2021.663778.


Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases.

Sadek M, Cachorro E, El-Armouche A, Kammerer S Int J Mol Sci. 2020; 21(20).

PMID: 33050419 PMC: 7590001. DOI: 10.3390/ijms21207462.


Endogenous Gαq-Coupled Neuromodulator Receptors Activate Protein Kinase A.

Chen Y, Granger A, Tran T, Saulnier J, Kirkwood A, Sabatini B Neuron. 2017; 96(5):1070-1083.e5.

PMID: 29154125 PMC: 5726796. DOI: 10.1016/j.neuron.2017.10.023.


Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells.

Keravis T, Favot L, Abusnina A, Anton A, Justiniano H, Soleti R PLoS One. 2015; 10(12):e0145291.

PMID: 26694325 PMC: 4687871. DOI: 10.1371/journal.pone.0145291.